Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2024-09-09 00:00:00 ET · period of report 2024-09-05 · accession 0001415889-24-023092 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-09 | 2024-09-05 | TVTX | Heerma Peter | Chief COMMERCIAL Off | A - Grant | $0.00 | +6,750 | 110.1K | +7% | $0 | |
| 2024-09-09 | 2024-09-09 | TVTX | Heerma Peter | Chief COMMERCIAL Off | S - Sale | $11.52 | -2,191 | 108.0K | -2% | -$25.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-05 | A | A | 6,750 | $0.00 | 110,149 | D | — | — | (F2) Includes 3,896 shares of Common Stock that were acquired by the Reporting Person on May 31, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-09-09 | S | D | 2,191 | $11.52 | 107,958 | D | — | — |